Expand APGE Menu
APGE MENU

APGE Latest Press Releases

-- March 26, 2026 --

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million Globe Newswire 4:01 PM

-- March 24, 2026 --

Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering Globe Newswire 9:53 PM

-- March 23, 2026 --

Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering Globe Newswire 4:01 PM
Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis Globe Newswire 6:30 AM

-- March 22, 2026 --

Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026 Globe Newswire 7:51 PM

-- March 2, 2026 --

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results Globe Newswire 7:00 AM

-- February 24, 2026 --

Apogee Therapeutics to Participate in Upcoming March Conferences Globe Newswire 7:30 AM

-- February 16, 2026 --

Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight PRNewswire 5:31 PM

-- February 5, 2026 --

Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026 Globe Newswire 8:00 AM

-- January 6, 2026 --

Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook Globe Newswire 6:00 AM

-- January 5, 2026 --

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026 Globe Newswire 4:01 PM
Market Data Delayed 15 Minutes